Good morning, all. Damian here with disappointing news on a closely watched gene therapy, an interesting deal in genome editing, and the long shadow of biotech’s slump.The need-to-know this morning• Shares of Sarepta Therapeutics are down 40% in pre-market trading, following disappointing results from a confirmatory study of its gene therapy for Duchenne muscular dystrophy […]
